[Evaluation of the nootropic effect of mebikar in clinical practice].
Mebicar therapy resulted in a reduction of the degree of deficient disorders of thinking in 27 of 50 patients with paranoid schizophrenia and normalization of indices of mental working capacity, attention and memory, shortening of the time of visual-motor disjunctive reaction in 50 patients with borderline states. Mebicar was shown to possess a nootropic effect which differs qualitatively from that of piracetam.
D000328:Adult; D001736:Biureas / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008606:Mental Processes / Q000187:drug effects*; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy / Q000523:psychology; D010889:Piracetam / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology; D013850:Thinking / Q000187:drug effects; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D001736:Biureas; D014149:Tranquilizing Agents; C015979:mebikar; D010889:Piracetam
Otsenka nootropnogo éffekta mebikara v klinicheskoĭ praktike.